Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3683013 | 1.00 | CA2 (0.34) | CA2L3MBTL1HCRTR1HCRTR2 | |
| SCHEMBL4421277 | 0.87 | RECQL (0.34) | CA2L3MBTL1HCRTR1HCRTR2 | |
| SCHEMBL13568693 | 0.87 | RECQL (0.34) | CA2L3MBTL1HCRTR1HCRTR2 | |
| SCHEMBL6065572 | 0.84 | L3MBTL1 (0.31) | L3MBTL1HCRTR1HCRTR2 | |
| SCHEMBL9695840 | 0.84 | L3MBTL1 (0.33) | L3MBTL1HCRTR1HCRTR2 | |
| SCHEMBL3218626 | 0.83 | LMNA (0.36) | CA2 | |
| SCHEMBL3218630 | 0.83 | LMNA (0.36) | CA2 | |
| SCHEMBL768274 | 0.83 | LMNA (0.36) | CA2 | |
| SCHEMBL475955 | 0.83 | LMNA (0.36) | CA2 | |
| SCHEMBL21049862 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2319853-B1 | Process for the production of 2'-branched nucleosides | IDENIX PHARMACEUTICALS INC (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-1976382-B1 | PROCESS FOR PREPARING A SYNTHETIC INTERMEDIATE FOR PREPARATION OF BRANCHED NUCLEOSIDES | IDENIX PHARMACEUTICALS INC (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-2319853-A1 | Process for the production of 2'-branched nucleosides | Idenix (Cayman) Limited (KY) | 2011-05-11 | — | — | EP | disclosed |
| US-7598373-B2 | Process for the production of 2-C-methyl-D-ribonolactone | IDENIX PHARMACEUTICALS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| EP-1976382-A2 | PROCESS FOR PREPARING A SYNTHETIC INTERMEDIATE FOR PREPARATION OF BRANCHED NUCLEOSIDES | IDENIX Pharmaceuticals, Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| EP-1585529-A4 | PROCESS FOR THE PRODUCTION OF 2'-BRANCHED NUCLEOSIDES | IDENIX CAYMAN LTD (KY) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007075876-A2 | PROCESS FOR PREPARING A SYNTHETIC INTERMEDIATE FOR PREPARATION OF BRANCHED NUCLEOSIDES | IDENIX PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| CN-1744903-A | Process for the preparation of 2' -branched nucleosides | IDENIX CAYMAN LTD (KY) | 2006-03-08 | — | — | CN | disclosed |
| EP-1585529-A2 | PROCESS FOR THE PRODUCTION OF 2'-BRANCHED NUCLEOSIDES | Idenix (Cayman) Limited (KY) | 2005-10-19 | — | — | EP | disclosed |
| US-20050020825-A1 | Process for the production of 2'-branched nucleosides | IDENIX PHARMACEUTICALS LLC | 2005-01-27 | — | — | US | disclosed |
| WO-2004052899-A2 | PROCESS FOR THE PRODUCTION OF 2'-BRANCHED NUCLEOSIDES | IDENIX (CAYMAN) LIMITED (KY) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020825-A1 | Process for the production of 2'-branched nucleosides | RNGTT, MTAP, NSUN2 | CA2 4424/4885L3MBTL1 472/4885HCRTR1 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.